Evaluate Esophageal Reinforcement With ACell MatriStem Surgical Matrix: A

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04159974` - RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus	Phase 2
Completed	`NCT03015389` - Wide Area Transepithelial Sample Esophageal Biopsy Combined With Computer Assisted 3-Dimensional Tissue Analysis (WATS3D) For the Detection of High Grade Esophageal Dysplasia and Adenocarcinoma
Terminated	`NCT04642690` - Nitrates and IL-8 in Barrett's Esophagus
Withdrawn	`NCT03982173` - Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors	Phase 2
Completed	`NCT02128243` - Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer	Phase 2
Recruiting	`NCT04430738` - Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers	Phase 1/Phase 2
Recruiting	`NCT04114136` - Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies	Phase 2
Terminated	`NCT03223662` - Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy	Phase 2
Recruiting	`NCT05530343` - Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance	N/A
Active, not recruiting	`NCT03539822` - Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies	Phase 1/Phase 2
Recruiting	`NCT05902988` - A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer	Phase 1/Phase 2
Recruiting	`NCT06071845` - Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples	N/A
Active, not recruiting	`NCT02872116` - Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer	Phase 3
Terminated	`NCT04089904` - Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal Adenocarcinoma	Phase 2
Recruiting	`NCT05177133` - Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus)	Phase 2
Recruiting	`NCT02962063` - Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer	Phase 1/Phase 2
Recruiting	`NCT02606396` - Cryotherapy for Malignant Dysphagia in Patients With Advanced Esophageal Cancer	N/A
Completed	`NCT02610764` - Pilot Sudy: Resectable Esophageal Adenocarcinoma and the Relevance of CTC	N/A
Terminated	`NCT00430027` - Preoperative Capecitabine, Oxaliplatin, Cetuximab, and Radiation Therapy for Locally Advanced Esophageal Adenocarcinoma	N/A
Recruiting	`NCT05642338` - A Multicenter Prospective Cohort Study Comparing Random Biopsies Versus Wide-Area Transepithelial Brush-Sampling (WATS) for Surveillance of Barrett's Esophagus, the WATS-EURO2 Study

NCT number	NCT01970306
Study type	Interventional
Source	Memorial Sloan Kettering Cancer Center
Contact
Status	Completed
Phase	Phase 2
Start date	October 18, 2013
Completion date	February 24, 2023

Evaluate Esophageal Reinforcement With ACell MatriStem Surgical Matrix: A Degradable Biologic Scaffold Material

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms